These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 6273562)

  • 1. Synthesis and beta-lactamase inhibitory properties of 2 beta-(chloromethyl)-2 alpha-methylpenam-3 alpha-carboxylic acid 1,1-dioxide.
    Gottstein WJ; Crast LB; Graham RG; Haynes UJ; McGregor DN
    J Med Chem; 1981 Dec; 24(12):1531-4. PubMed ID: 6273562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and beta-lactamase inhibitory properties of 2 beta-[(1,2,3-triazol-1-yl)methyl]-2 alpha-methylpenam-3 alpha-carboxylic acid 1,1-dioxide and related triazolyl derivatives.
    Micetich RG; Maiti SN; Spevak P; Hall TW; Yamabe S; Ishida N; Tanaka M; Yamazaki T; Nakai A; Ogawa K
    J Med Chem; 1987 Aug; 30(8):1469-74. PubMed ID: 3039137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and beta-lactamase inhibitory properties of 2 beta-[(acyloxy)methyl]-2-methylpenam-3 alpha-carboxylic acid 1,1-dioxides.
    Gottstein WJ; Haynes UJ; McGregor DN
    J Med Chem; 1985 Apr; 28(4):518-22. PubMed ID: 3872369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and antimicrobial evaluation of 2 beta-chloromethyl-6 beta-carbamoylmethyl-penam-1,1-dioxide-3-carboxylic acid.
    Gaviraghi G; Perboni A; Tamburini B; Xerri L; Salvatori A; Spadoni G; Tarzia G
    Farmaco; 1996 Jul; 51(7):535-8. PubMed ID: 8765676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Susceptibility of clinical isolates to expanded-spectrum beta-lactams alone and in the presence of beta-lactamase inhibitors.
    Qadri SM; Ueno Y; Cunha BA
    Chemotherapy; 1996; 42(5):334-42. PubMed ID: 8874972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of beta-lactamase inhibitors in chemotherapy.
    Neu HC
    Pharmacol Ther; 1985; 30(1):1-18. PubMed ID: 3018803
    [No Abstract]   [Full Text] [Related]  

  • 7. 6-beta-bromo- and 6-beta-iodo penicillanic acid, two novel beta-lactamase inhibitors.
    Wise R; Andrews JM; Patel N
    J Antimicrob Chemother; 1981 May; 7(5):531-6. PubMed ID: 6267005
    [No Abstract]   [Full Text] [Related]  

  • 8. Synthesis of new C-6 alkyliden penicillin derivatives as beta-lactamase inhibitors.
    Di Giacomo B; Tarzia G; Bedini A; Gatti G; Bartoccini F; Balsamini C; Tontini A; Baffone W; Di Modugno E; Felici A
    Farmaco; 2002 Apr; 57(4):273-83. PubMed ID: 11989807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beta-lactamase inactivation by mechanism-based reagents.
    Fisher J; Belasco JG; Charnas RL; Khosla S; Knowles JR
    Philos Trans R Soc Lond B Biol Sci; 1980 May; 289(1036):309-19. PubMed ID: 6109326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological evaluation of 6-bromo-6-substituted penicillanic acid derivatives as beta-lactamase inhibitors.
    Bedini A; Balsamini C; Di Giacomo B; Tontini A; Citterio B; Giorgi L; Di Modugno E; Tarzia G
    Farmaco; 2002 Aug; 57(8):663-9. PubMed ID: 12361234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The history and background of Augmentin.
    Rolinson GN
    S Afr Med J; 1982 Jul; 62(5 Spec No):3A-4A. PubMed ID: 6979804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 6-(Methoxymethylene)penicillanic acid: inactivator of RTEM beta-lactamase from Escherichia coli.
    Brenner DG; Knowles JR
    Biochemistry; 1984 Nov; 23(24):5839-46. PubMed ID: 6098300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Beta-lactamase inhibitors. II. Synthesis and biological properties of 6-sulfonylaminopenicillanic acids].
    Kazimierczak J; Mikołajczyk J; Kotulowa W; Cieślak J
    Acta Pol Pharm; 1984; 41(6):619-23. PubMed ID: 6100225
    [No Abstract]   [Full Text] [Related]  

  • 14. Synthesis of new sulfonylamido-penicillanic acid sulfones inhibitors of beta-lactamases.
    Vanwetswinkel S; Fastrez J; Marchand-Brynaert J
    J Antibiot (Tokyo); 1994 Sep; 47(9):1041-51. PubMed ID: 7928692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of inhibitors of beta-lactamases on beta-lactamase extracts and on intact cells.
    Li JT; Moosdeen F; Williams JD
    J Antimicrob Chemother; 1982 Apr; 9(4):287-96. PubMed ID: 6282800
    [No Abstract]   [Full Text] [Related]  

  • 16. Penicillanic acid sulfone: nature of irreversible inactivation of RTEM beta-lactamase from Escherichia coli.
    Brenner DG; Knowles JR
    Biochemistry; 1984 Nov; 23(24):5833-9. PubMed ID: 6098299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clavulanic acid and CP-45,899: a comparison of their in vitro activity in combination with penicillins.
    Wise R; Andrews JM; Bedford KA
    J Antimicrob Chemother; 1980 Mar; 6(2):197-206. PubMed ID: 6247316
    [No Abstract]   [Full Text] [Related]  

  • 18. Clavulanic acid and amoxycillin: a clinical, bacteriological, and pharmacological study.
    Ball AP; Geddes AM; Davey PG; Farrell ID; Brookes GR
    Lancet; 1980 Mar; 1(8169):620-3. PubMed ID: 6102627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of four beta-lactamase inhibitors in combination with ampicillin against Mycobacterium tuberculosis.
    Sorg TB; Cynamon MH
    J Antimicrob Chemother; 1987 Jan; 19(1):59-64. PubMed ID: 3030999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-vitro evaluation of the four beta-lactamase inhibitors: BRL42715, clavulanic acid, sulbactam, and tazobactam.
    Muratani T; Yokota E; Nakane T; Inoue E; Mitsuhashi S
    J Antimicrob Chemother; 1993 Sep; 32(3):421-9. PubMed ID: 8262864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.